spacer

Proteins in PDB homologous to 1a30A

Additional 1a30 chains
1a30B

185 proteins (1193 PDB structures) with E() < 0.001

Homologs in SwissProt


Acc   E.C. E() % id alen 25
*D
27
%G
1hpoA, 1hpoB, 1a30A, 1a30B, 1a8kA, 1a8kB, 1a8kD, 1a8kE, 1d4yA, 1d4yB, 1mrwA, 1mrwB, 1msmA, 1msmB, 1ztzA, 1ztzB, 2pk5A, 2pk5B, 2pk6A, 2pk6B, 3i8wA, 3kdbA, 3kdbB, 3kddA, 3kddB, 3kdcA, 3kdcB, 3nlsA, 3nlsB, 3th9A, 3th9B, 3qbfA, 3qbfB, 3qihA, 3qihB, 3qn8A, 3qn8B, 3qp0A, 3qp0B, 3qpjA, 3qpjB, 3qrmA, 3qrmB, 3qroA, 3qroB, 3qrsA, 3qrsBHiv-1 Protease Triple MutantU103265 COMP2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.7e-47100.099 *D%G
3tlhA, 1zpaA, 1zp8A, 2o4kA, 2o4kB, 2o4pA, 2o4pB, 2o4sA, 2o4sB, 2p3bAStructural Studies Of Hiv And Fiv Protea2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.168.2e-4798.099 *D%G
1aaqA, 1aaqBHydroxyethylene Isostere Inhibitors Of H2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.169.8e-4798.099 *D%G
2o4lA, 2o4lBHiv-1 Protease (Q7k, I50v) In Complex Wi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.169.8e-4797.099 *D%G
1mrxA, 1mrxB, 1msnA, 1msnBHiv Protease (Mutant Q7k L33i L63i V82f 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.169.8e-4798.099 *D%G
1hosA, 1hosB, 1hteA, 1hteB, 1htfA, 1htfB, 1htgA, 1htgB, 1hpsA, 1hpsB, 1hpvA, 1hpvB, 1hbvA, 1hbvB, 1hihA, 1hihB, 1hpxA, 1hpxB, 1hsgA, 1hsgB, 2upjA, 2upjB, 1gnoA, 1gnoB, 7upjA, 7upjB, 1ajvA, 1ajvB, 1ajxA, 1ajxB, 2bpvA, 2bpvB, 2bpwA, 2bpwB, 2bpxA, 2bpxB, 2bpyA, 2bpyB, 2bpzA, 2bpzB, 1c70A, 1c70B, 1fqxA, 1fqxB, 1g35A, 1g35B, 1g2kA, 1g2kB, 1iiqA, 1iiqB, 1d4hA, 1d4hB, 1d4iA, 1d4iB, 1d4jA, 1d4jB, 1ebwA, 1ebwB, 1ebzA, 1ebzB, 1ec0A, 1ec0B, 1ec1A, 1ec1B, 1ec2A, 1ec2B, 1ec3A, 1ec3B, 1muiB, 1muiA, 1npvA, 1npvB, 1npwA, 1npwB, 1m0bA, 1m0bB, 1npaA, 1npaB, 1nh0A, 1nh0B, 1t7kA, 1t7kB, 1u8gA, 1u8gB, 1wbkA, 1wbkB, 1wbmA, 1wbmB, 1yt9A, 1yt9B, 1xl2A, 1xl2B, 1xl5A, 1xl5B, 1sp5A, 1sp5B, 2a4fA, 2a4fB, 2bb9A, 2bb9B, 2bbbA, 2bbbB, 2bqvA, 2bqvB, 2aquA, 2aquB, 2cejA, 2cejB, 2cemA, 2cemB, 2cenA, 2cenB, 1hhpA, 1upjA, 3phvA, 2pqzA, 2pqzB, 2pwcA, 2pwcB, 2pwrA, 2pwrB, 2qnnA, 2qnnB, 2qnpA, 2qnpB, 2qnqA, 2qnqB, 2uxzA, 2uxzB, 2uy0A, 2uy0B, 3bgbA, 3bgbB, 3bgcA, 3bgcB, 3bheA, 3bheB, 2zgaA, 3cktA, 3cktB, 3ggaG, 3ggaH, 3ggaA, 3ggaB, 3ggaC, 3ggaD, 3ggvB, 3ggvA, 3ggvC, 3ggvD, 3ggvE, 3ggvF, 3ggvG, 3ggvH, 3ggvI, 3ggxA, 3ggxB, 3ggxC, 3ggxD, 3ggxE, 3ggxF, 3ggxG, 3ggxH, 2wkzA, 2wkzB, 3psuA, 4fe6A, 3t11A, 3t11B, 1ohrA, 1ohrBInhibition Of Human Immunodeficiency Vir2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.7e-4697.099 *D%G
2az8A, 2hb4A, 2pc0A, 3kf0A, 3kf0B, 3kfnA, 3kfnB, 3kfpA, 3kfrA, 3kfrB, 3kfsA, 3kfsB, 4e43A, 4e43B, 4ejdA, 4ejdB, 4ejkA, 4ejkBHiv-1 Protease Nl4-3 In Complex With Inh2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.7e-4697.099 *D%G
2fdeA, 2fdeBWild Type Hiv Protease Bound With Gw03852.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.7e-4697.099 *D%G
1w5yA, 1w5yB, 1w5vA, 1w5vB, 1w5wA, 1w5wB, 1w5xA, 1w5xBHiv-1 Protease In Complex With Fluoro Su2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.9e-4697.099 *D%G
1hxbA, 1hxbB, 1odwA, 1odwBHiv-1 Proteinase Complexed With Ro 31-892.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.1e-4696.099 *D%G
2r38A, 2r38B, 2r3wA, 2r3wB, 3bc4AI84v Hiv-1 Protease Mutant In Complex Wi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.1e-4696.099 *D%G
2r3tA, 2r3tB, 2r43A, 2r43BI50v Hiv-1 Protease Mutant In Complex Wi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.1e-4696.099 *D%G
1bv9A, 1bv9B, 1merA, 1merB, 1mesA, 1mesBHiv-1 Protease (I84v) Complexed With Xv62.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.5e-4694.999 *D%G
1tcxA, 1tcxBHiv Triple Mutant Protease Complexed Wit2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163e-4693.999 *D%G
1axaA, 1axaBActive-Site Mobility In Human Immunodefi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.6e-4696.099 *D%G
5hvpA, 5hvpB, 9hvpA, 9hvpB, 4phvA, 4phvB, 1sbgA, 1sbgB, 1proA, 1proB, 1a8gA, 1a8gB, 1vikA, 1vikB, 1vijA, 1vijB, 1ebyA, 1ebyB, 1izhA, 1izhB, 2hvpA, 2qmpA, 2qmpB, 3m9fA, 3m9fB, 3s85A, 3s85B, 3s85C, 3s85D, 3s85E, 3s85F, 3s85G, 3s85H, 3s85I, 3s85J, 3s85K, 3s85L, 1hxwA, 1hxwBCrystallographic Analysis Of A Complex B2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.6e-4696.099 *D%G
1hvcAA Tethered Dimer Of Hiv-1 Protease Compl4e-4697.099 *D%G
2az9AHiv-1 Protease Nl4-3 1x Mutant2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.3e-4696.099 *D%G
1g6lA1.9a Tethered Hiv-1 Protease2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.8e-4696.099 *D%G
2qhcA, 2qhcBThe Influence Of I47a Mutation On Reduce2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.2e-4696.099 *D%G
2z54A, 2z54BThe Influence Of I47a Mutation On Reduce2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.3e-4694.999 *D%G
1bv7A, 1bv7B, 1metA, 1metBCounteracting Hiv-1 Protease Drug Resist2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.3e-4694.999 *D%G
3qozA, 3qozBWild-Type Hiv Protease In Complex With D2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.3e-4694.999 *D%G
1d4sA, 1d4sBHiv-1 Protease V82fI84V DOUBLE MUTANTTIP2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.3e-4694.999 *D%G
1bwaA, 1bwaB, 1meuA, 1meuB, 1bwbA, 1bwbBHiv-1 Protease (V82fI84V) DOUBLE MUTANT 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.6e-4693.999 *D%G
1gnnA, 1gnnBHiv-1 Protease Mutant With Val 82 Replac2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.6e-4696.099 *D%G
1hefE, 1hegEThe Crystal Structures At 2.2 Angstroms 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.169.1e-4696.099 *D%G
1gnmA, 1gnmBHiv-1 Protease Mutant With Val 82 Replac2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.169.1e-4696.099 *D%G
2fleA, 2fleBStructural Analysis Of Asymmetric Inhibi9.1e-4694.999 *D%G
1odxA, 1odxBHiv-1 Proteinase Mutant A71t, V82a2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.1e-4594.999 *D%G
1odyA, 1odyBHiv-1 Protease Complexed With An Inhibit2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.1e-4594.999 *D%G
1difA, 1difB, 1hviA, 1hviB, 1hvjA, 1hvjB, 1hvkA, 1hvkB, 1hvlA, 1hvlBHiv-1 Protease In Complex With A Difluor2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.1e-4596.998 *D%G
1a9mA, 1a9mBG48h Mutant Of Hiv-1 Protease In Complex2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.1e-4596.099 *D%G
2p3bBThe Subtype B Wild Type Hiv Protease Com2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.3e-4597.099 *D%G
2wl0A, 2wl0B, 2xyeA, 2xyeB, 2xyfA, 2xyfB, 4a6bA, 4a6bB, 4a6cA, 4a6cB, 4a4qA, 4a4qBHiv-1 Protease Inhibitors Containing A T2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.3e-4594.999 *D%G
1lzqA, 1lzqB, 1zlfA, 1zlfB, 1zj7AThe Complex Of Mutant Hiv-1 Protease (A72.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.3e-4593.999 *D%G
1bv9A, 1bv9B, 1merA, 1merB, 1mesA, 1mesBHiv-1 Mutant (I84v) Protease Complexed W2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.6e-4594.998 *D%G
2f3kA, 2f3kB, 2i0aA, 2i0aB, 2i0dA, 2i0dB, 2psuA, 2psuB, 2psvA, 2psvB, 2q54A, 2q54B, 2q55A, 2q55B, 2q5kA, 2q5kB, 2q3kA, 2q3kB, 2qhyA, 2qhyB, 2qhzA, 2qhzB, 2qi0A, 2qi0B, 2qi1A, 2qi1B, 2qi3A, 2qi3B, 2qi4A, 2qi4B, 2qi5A, 2qi5B, 2qi6A, 2qi6B, 2qi7A, 2qi7B, 3ekvA, 3ekvB, 3ekxA, 3ekxB, 3ekyA, 3ekyB, 3gi4A, 3gi4B, 3gi5A, 3gi5B, 3gi6A, 3gi6B, 3mxdA, 3mxdB, 3mxeA, 3mxeB, 3o99A, 3o99B, 3o9aA, 3o9aB, 3o9bA, 3o9bB, 3o9cA, 3o9cB, 3o9dA, 3o9dB, 3o9eA, 3o9eB, 3o9fA, 3o9fB, 3o9gA, 3o9gB, 3o9hA, 3o9hB, 3o9iA, 3o9iB, 3r4bA, 3r4bB, 3sa3A, 3sa3B, 3sa4A, 3sa4B, 3sa5A, 3sa5B, 3sa6A, 3sa6B, 3sa7A, 3sa7B, 3sa8A, 3sa8B, 3sa9A, 3sa9B, 3saaA, 3saaB, 3sabA, 3sabB, 3sacA, 3sacB, 4djoA, 4djoB, 4djpA, 4djpB, 4djqA, 4djqB, 4djrA, 4djrBSubstrate Envelope And Drug Resistance: 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.6e-4594.999 *D%G
1ytgA, 1ytgB, 1ythA, 1ythB, 2aidA, 2aidB, 1t3rA, 1t3rB, 1kzkA, 1kzkB, 3el1A, 3el1B, 3i7eA, 3i7eB, 4f73A, 4f73B, 4f74A, 4f74B, 4f75A, 4f75B, 4f76A, 4f76BSiv Protease Crystallized With Peptide P2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.9e-4593.999 *D%G
1k6cA, 1k6cB, 1k6pA, 1k6pB, 1k6tA, 1k6tB, 1k6vA, 1k6vB, 1t7iA, 1t7iB, 1t7jA, 1t7jB, 3el5A, 3el5BLack Of Synergy For Inhibitors Targeting2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.3e-4593.999 *D%G
5hvpA, 5hvpB, 9hvpA, 9hvpB, 4phvA, 4phvB, 1sbgA, 1sbgB, 1proA, 1proB, 1a8gA, 1a8gB, 1vikA, 1vikB, 1vijA, 1vijB, 1ebyA, 1ebyB, 1izhA, 1izhB, 2hvpA, 2qmpA, 2qmpB, 3m9fA, 3m9fB, 3s85A, 3s85B, 3s85C, 3s85D, 3s85E, 3s85F, 3s85G, 3s85H, 3s85I, 3s85J, 3s85K, 3s85L, 1hxwA, 1hxwBHiv-1 Protease Dimer Complexed With A-842.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.3e-4595.998 *D%G
2o4nA, 2o4nBHiv-1 Protease (Trm Mutant) In Complex W2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.3e-4592.999 *D%G
1rl8A, 1rl8BThe Complex Of Resistant Strain Of Hiv-12.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.3e-4594.999 *D%G
2q64A, 2q64BHiv-1 Pr Mutant In Complex With Nelfinav2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4594.999 *D%G
2i4uA, 2i4uB, 2i4wA, 2i4wB, 2i4dA, 2i4dBHiv-1 Protease With Tmc-1262.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4596.099 *D%G
1hvhA, 1hvhB, 1qbuA, 1qbuB, 1qbtA, 1qbtB, 1qbrA, 1qbrBNonpeptide Cyclic Cyanoguanidines As Hiv2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4594.999 *D%G
1hvsA, 1hvsBStructural Basis Of Drug Resistance For 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4595.998 *D%G
1iziA, 1iziBInhibitor Of Hiv Protease With Unusual B2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4592.999 *D%G
2q63A, 2q63B, 2qakA, 2qakBHiv-1 Pr Mutant In Complex With Nelfinav2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4593.999 *D%G
1zsfA, 1zsfB, 1zsrA, 1zsrBComplex Of A Hydroxyethylamine Inhibitor2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4596.099 *D%G
1fb7AAn In Vivo Hiv-1 Protease Mutant In Comp2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4593.999 *D%G
3mimBX-Ray Snapshot Of Hiv-1 Protease In Acti2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163e-4594.999 *D%G
2fguA, 2fguBX-Ray Hiv-1 Protease T80s Variant In Com2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.4e-4592.999 *D%G
2nphA, 2nphB, 3mimAHiv1 Protease In Situ Product Complex2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.4e-4594.999 *D%G
3oy4A, 3oy4BHiv-1 L76v Protease In Complex With The 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.4e-4593.999 *D%G
1hivA, 1hivBA Complex Of Hiv-1 Protease With A Dihyd2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.4e-4594.999 *D%G
1aidA, 1aidBA Non-Peptide Inhibitor Complexed With H2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164e-4592.999 *D%G
1bv7A, 1bv7B, 1metA, 1metBHiv-1 Mutant (V82f) Protease Complexed W2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164e-4594.998 *D%G
2azbAHiv-1 Protease Nl4-3 3x Mutant In Comple2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164e-4593.999 *D%G
3el4A, 3el4BInhibitor Saquinavir (Sqv) Complexed Wit2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4592.999 *D%G
2fgvA, 2fgvBX-Ray Hiv-1 Protease T80n Variant In Com2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4592.999 *D%G
2i4vA, 2i4vB, 2i4xA, 2i4xBHiv-1 Protease I84v, L90m With Tmc1262.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4593.999 *D%G
1bwaA, 1bwaB, 1meuA, 1meuB, 1bwbA, 1bwbBHiv-1 Protease (V82fI84V) DOUBLE MUTANT 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4593.998 *D%G
2nxdA, 2nxdB, 2nxlA, 2nxlB, 2nxmA, 2nxmBHiv-1 Protease D25n Complexed With Rt-Rh2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4593.999 *N%G
1fgcC, 1fgcD, 1sdtA, 1sdtB, 2aodA, 2aodB, 2aoiA, 2aoiB, 2aojA, 2aojB, 2hb3A, 2hb3B, 2ienA, 2ienB, 3b7vA, 3b7vB, 2z4oA, 2z4oB, 3djkA, 3djkB, 3fx5A, 3fx5B, 3dk1A, 3dk1B, 3h5bA, 3h5bB, 3i6oA, 3i6oB, 3a2oA, 3a2oB, 3k4vC, 3k4vD, 3nu3A, 3nu3B, 3ok9A, 3ok9B, 3oxcA, 3oxcB, 3ndwA, 3ndwB, 3ndxA, 3ndxB, 3st5A, 3st5B, 3qaaA, 3qaaB, 4dfgA, 4dfgB, 3tofA, 3tofB, 3togA, 3togB, 3togC, 3togD, 3tohA, 3tohB, 4fl8A, 4fl8B, 2a1eA, 2a1eBStructural Implications Of Drug Resistan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4598.099 *D%G
3oxvB, 3oxvA, 3oxvD, 3oxvCHiv-1 I50v, A71 Protease In Complex With2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4592.999 *D%G
3k4vA, 3k4vB, 3ndtA, 3ndtB, 3ndtC, 3ndtD, 3nduA, 3nduB, 3nduC, 3nduDNew Crystal Form Of Hiv-1 ProteaseSAQUIN2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.9e-4598.099 *D%G
3tkgA, 3tkgB, 3tkgC, 3tkgD, 3tkwA, 3tkwB, 3tl9A, 3tl9BHiv Model Protease PrecursorSAQUINAVIR C5.1e-4598.099 *D%G
2hs1A, 2hs1B, 3nu4A, 3nu4B, 4fm6B, 4fm6AUltra-High Resolution X-Ray Hiv-1 Protea2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.9e-4597.099 *D%G
2avqA, 2avqB, 2avsA, 2avsB, 2f8gA, 2f8gB, 2qd6A, 2qd6B, 3cyxA, 3cyxB, 3nu5A, 3nu5BKinetics, Stability, And Structural Chan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.9e-4597.099 *D%G
3b80A, 3b80B, 3d1yA, 3d1yB, 3d20A, 3d20B, 3nujA, 3nujBHiv-1 Protease Mutant I54v Complexed Wit2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.9e-4597.099 *D%G
3el9A, 3el9BAtazanavir (Atv) In Complex With A Multi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.9e-4591.999 *D%G
2aocA, 2aocB, 2ieoA, 2ieoB, 2nnkA, 2nnkB, 2nnpA, 2nnpB, 2qd8A, 2qd8B, 3nu9A, 3nu9BCrystal Structure Analysis Of Hiv-1 Prot2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.9e-4597.099 *D%G
1f7aA, 1f7aB, 1kj4A, 1kj4B, 1kj4C, 1kj4D, 1kj7A, 1kj7B, 1kjfA, 1kjfB, 1kjgA, 1kjgB, 1kjhA, 1kjhB, 1tsuA, 1tsuB, 2fnsA, 2fnsBHow Does A Symmetric Dimer Recognize An 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.9e-4592.999 *N%G
3oxwA, 3oxwB, 3oxwC, 3oxwD, 3oxxA, 3oxxB, 3oxxC, 3oxxDHiv-1 I50v, A71v Protease In Complex Wit2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.9e-4591.999 *D%G
1lv1A, 3doxA, 2whhACrystal Structure Analysis Of The Non-Ac2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.4e-4594.999 *D%G
2pynA, 2pynBHiv-1 Pr Mutant In Complex With Nelfinav2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.1e-4593.999 *D%G
1dw6C, 1dw6D, 1fejC, 1fejD, 1sduA, 1sduB, 2f81A, 2f81B, 3nuoA, 3nuoBStructural And Kinetic Analysis Of Drug 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.1e-4597.099 *D%G
2pymA, 2pymBHiv-1 Pr Mutant In Complex With Nelfinav2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.1e-4593.999 *D%G
3em3A, 3em3BAmprenavir (Apv) In Complex With A Drug 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.1e-4592.999 *D%G
2avmA, 2avmB, 2avoA, 2avoBKinetics, Stability, And Structural Chan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.168.5e-4597.099 *D%G
3em4A, 3em4B, 3em4U, 3em4V, 3em6A, 3em6BAtazanavir (Atv) In Complex With I50lA712.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.168.5e-4591.999 *D%G
3d1zA, 3d1zB, 3d1xA, 3d1xB, 3nu6A, 3nu6BHiv-1 Mutant I54m And Inhibitor Darunavi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.168.5e-4597.099 *D%G
3s43B, 3s53A, 3s53B, 3s54A, 3s54B, 3s56A, 3s56BHiv-1 Protease Triple Mutants V32i, I47v8.5e-4594.999 *D%G
2r5pA, 2r5pB, 2r5pC, 2r5pD, 2r5qA, 2r5qB, 2r5qC, 2r5qD, 2r8nACrystal Structure Analysis Of Hiv-1 Subt2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.168.5e-4591.999 *D%G
2hs2A, 2hs2BM46l Mutant Of Hiv-1 Protease Complexed 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161e-4497.099 *D%G
3pwmA, 3pwmB, 3pwrA, 3pwrB, 3vf7A, 3vf7BHiv-1 Protease Mutant L76v With Darunavi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161e-4497.099 *D%G
1mtbA, 1mtbBViability Of A Drug-Resistant Hiv-1 Prot2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-4491.999 *N%G
1sdvA, 1sdvB, 2aoeA, 2aoeB, 2aofA, 2aofB, 2aogA, 2aogB, 2aohA, 2aohB, 2idwA, 2idwB, 2nmyA, 2nmyB, 2nmzA, 2nmzB, 2qd7A, 2qd7B, 3vfaA, 3vfaBCrystal Structures Of Hiv Protease V82a 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-4497.099 *D%G
1fg6C, 1fg6D, 1fg8C, 1fg8D, 3vfbA, 3vfbBStructural Implications Of Drug Resistan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-4497.099 *D%G
3aidAA New Class Of Hiv-1 Protease Inhibitor:2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-4493.998 *D%G
1a94A, 1a94B, 1a94D, 1a94EStructural Basis For Specificity Of Retr2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-4497.099 *D%G
1fffC, 1fffD, 1ffiC, 1ffiD, 2f80A, 2f80B, 2qciA, 2qciBStructural Implications Of Drug Resistan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.5e-4497.099 *D%G
1mt7A, 1mt7B, 1mt8A, 1mt8B, 1mt9A, 1mt9B, 1n49A, 1n49B, 1n49C, 1n49D, 1tsqA, 1tsqB, 2fntA, 2fntBViability Of A Drug-resistant Hiv-1 Prot2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.5e-4491.999 *N%G
1ebkC, 1ebkD, 1ebkE, 1ebkFStructural And Kinetic Analysis Of Drug 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.5e-4497.099 *D%G
3bvaA, 3bvaB, 3bvbA, 3bvbBCystal Hiv-1 Active Site Mutant D25n And2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.5e-4497.099 *N%G
3lzvA, 3lzvBNelfinavir-Resistant Hiv-1 Protease (D302.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.5e-4491.999 *D%G
2g69AUnliganded Hiv-1 Protease F53l Mutant2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.8e-4497.099 *D%G
1bvgA, 1bvgB, 1bveA, 1bveB, 1hwrA, 1hwrBHiv-1 Protease-Dmp323 Complex In Solutio2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.8e-4494.998 *D%G
1k2bA, 1k2bBCombining Mutations In Hiv-1 Protease To2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.8e-4496.099 *D%G
3kt5AN88s Mutant Hiv-1 Protease2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162e-4493.999 *D%G
3kt2AN88d Mutant Hiv-1 Protease2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162e-4493.999 *D%G
2avvA, 2avvB, 2avvD, 2avvEKinetics, Stability, And Structural Chan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.2e-4497.099 *D%G
2azcA, 2azcB, 2hb2A, 2hc0A, 2hc0BHiv-1 Protease Nl4-3 6x Mutant2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.2e-4491.999 *D%G
3lzsA, 3lzsBHiv-1 Crf01_ae Protease In Complex With 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.2e-4490.999 *D%G
1zbgA, 1zbgB, 1zpkA, 1zpkBA Complex Of Mutant Hiv-1 Protease (A71v2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.2e-4492.999 *D%G
3jw2A, 3jw2BHiv-1 Protease Mutant G86s With Darunavi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.2e-4497.099 *D%G
3jvwA, 3jvwB, 3jvyA, 3jvyBHiv-1 Protease Mutant G86a With Symmetri2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.2e-4497.099 *D%G
3s43AHiv-1 Protease Triple Mutants V32i, I47v2.2e-4493.999 *D%G
1dazC, 1dazD, 1ff0C, 1ff0DStructural And Kinetic Analysis Of Drug 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.6e-4497.099 *D%G
2b60A, 2b60BHiv-1 Protease Mutant Bound To Ritonavir3.1e-4490.999 *D%G
1bdrA, 1bdrBHiv-1 (2: 31, 33-37) Protease Complexed 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.1e-4491.999 *D%G
1fgcC, 1fgcD, 1sdtA, 1sdtB, 2aodA, 2aodB, 2aoiA, 2aoiB, 2aojA, 2aojB, 2hb3A, 2hb3B, 2ienA, 2ienB, 3b7vA, 3b7vB, 2z4oA, 2z4oB, 3djkA, 3djkB, 3fx5A, 3fx5B, 3dk1A, 3dk1B, 3h5bA, 3h5bB, 3i6oA, 3i6oB, 3a2oA, 3a2oB, 3k4vC, 3k4vD, 3nu3A, 3nu3B, 3ok9A, 3ok9B, 3oxcA, 3oxcB, 3ndwA, 3ndwB, 3ndxA, 3ndxB, 3st5A, 3st5B, 3qaaA, 3qaaB, 4dfgA, 4dfgB, 3tofA, 3tofB, 3togA, 3togB, 3togC, 3togD, 3tohA, 3tohB, 4fl8A, 4fl8B, 2a1eA, 2a1eBHigh Resolution Hiv-1 Pr With Ts-1262.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.1e-4498.098 *D%G
1k1uA, 1k1uBCombining Mutations In Hiv-1 Protease To2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.8e-4496.099 *D%G
4dqbA, 4dqbBWild-Type Hiv-1 Protease In Complex With3.8e-4494.999 *D%G
1bdlA, 1bdlBHiv-1 (2:31-37) Protease Complexed With 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.8e-4490.999 *D%G
1sguA, 1sguB, 1sh9A, 1sh9BComparing The Accumulation Of Active Sit2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.5e-4488.999 *D%G
2fxeA, 2fxeBX-Ray Hiv-1 Protease Crm Mutant Complexe2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.5e-4493.999 *D%G
1hvrA, 1hvrB, 1qbsA, 1qbsBRational Design Of Potent, Bioavailable,2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.5e-4493.999 *D%G
3cywA, 3cywBEffect Of Flap Mutations On Hiv-1 Protea2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.5e-4497.099 *D%G
1bdqA, 1bdqBHiv-1 (2:31-37, 47, 82) Protease Complex2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.5e-4488.999 *D%G
1z8cA, 1z8cBThe Complex Of Mutant Hiv-1 Protease (L62.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.5e-4492.999 *D%G
3aidBA New Class Of Hiv-1 Protease Inhibitor:2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.5e-4493.897 *D%G
1k2cA, 1k2cBCombining Mutations In Hiv-1 Protease To2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.5e-4496.099 *D%G
3lzuB, 3lzuAA Nelfinavir Resistant Hiv-1 Crf01_ae Pr2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.6e-4489.999 *D%G
3n3iAG48v/c95f Tethered Hiv-1 Protease/saquin2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.2e-4493.999 *D%G
3ekqA, 3ekqBInhibitor Saquinavir (Sqv) In Complex Wi2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.9e-4490.999 *D%G
3ekpA, 3ekpB, 3ekpC, 3ekpD, 3ektA, 3ektB, 3ektC, 3ektD, 3ekwA, 3ekwB, 3el0A, 3el0BThe Inhibitor Amprenavir (Apv) In Comple2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.9e-4490.999 *D%G
1k1tA, 1k1tBCombining Mutations In Hiv-1 Protease To2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.169.6e-4496.099 *D%G
2b7zB, 2b7zAHiv-1 Protease Mutant Bound To Indinavir2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.169.6e-4488.999 *D%G
3so9A, 3so9B, 3spkA, 3spkBDarunavir In Complex With A Human Immuno2.4e-4386.999 *N%G
1mtrA, 1mtrB, 1b6kA, 1b6kB, 1b6lA, 1b6lB, 1b6mA, 1b6mB, 1b6pA, 1b6pB, 1d4lA, 1d4lB, 1d4kA, 1d4kB, 1z1hA, 1z1hB, 1z1rA, 1z1rB, 3bxsA, 3bxsBHiv-1 Protease Complexed With A Cyclic P2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.9e-4392.999 *D%G
1dmpA, 1dmpBHiv-1 Protease Complex2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.9e-4393.998 *D%G
2p3aA, 2p3aBThe Multi-Drug Resistant Mutant Subtype 2.9e-4389.999 *D%G
3d3tA, 3d3tBHiv-1 Crf01_ae In Complex With The Subst3.5e-4387.999 *N%G
1c6xA, 1c6xB, 1c6yA, 1c6yB, 1c6zA, 1c6zBAlternate Binding Site For The P1-P3 Gro3.5e-4388.999 *D%G
2je4A, 2je4BAtomic-Resolution Chemically-Synthesized2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.5e-4391.999 *D%G
1q9pASolution The Mature Hiv-1 Protease Monom2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164e-4398.994 *D%G
3otyA, 3otyB, 3ou1A, 3ou3A, 3ou3B, 3ou4A, 3ouaA, 3ouaB, 3oubA, 3oubB, 3oucA, 3oucB, 3oudA, 3oq7A, 3r0wA, 3r0wB, 3r0yA, 3r0yB, 4faeA, 4faeB, 4fafA, 4fafB, 4eyrA, 4eyrBMdr769 Hiv-1 Protease Complexed With RtR2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.1e-4385.999 *N%G
3ou1B, 3ou4BMdr769 Hiv-1 Protease Complexed With RhI2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.1e-4385.999 *N%G
1rpiA, 1rpiB, 1rq9A, 1rq9B, 1rv7A, 1rv7B, 1tw7A, 1tw7B, 3otsA, 3otsBCrystal Structures Of A Multidrug-Resist2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.1e-4385.999 *N%G
3oqdACrystal Structures Of Multidrug-Resistan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.1e-4385.999 *N%G
3pj6ACrystal Structures Of Multidrug-Resistan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.1e-4385.999 *N%G
3ixoA, 3ixoBUncomplexed Hiv_1 Protease Subtype A2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166.1e-4387.999 *D%G
2fxdA, 2fxdBX-Ray Hiv-1 Protease Irm Mutant Complexe6.1e-4389.999 *D%G
4dqfA, 4dqfB(G16aL38A) HIV-1 Protease In Complex Wit6.1e-4392.999 *D%G
4dqhA, 4dqhB(R14cE65C) HIV-1 Protease In Complex Wit6.1e-4393.999 *D%G
3oqaACrystal Structures Of Multidrug-Resistan2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.167.4e-4385.999 *N%G
3bxrA, 3bxrBCrystal Structures Of Highly Constrained2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.168.9e-4391.999 *N%G
4hvpA, 4hvpB, 7hvpA, 7hvpB, 8hvpA, 8hvpB, 1cpiA, 1cpiB, 1b6jA, 1b6jB, 3hvpAComplex Of Synthetic Hiv-1 Protease With2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.1e-4290.999 *D%G
4dqcA, 4dqcB, 4dqeA, 4dqeB, 4dqgA, 4dqgB(G16cL38C) HIV-1 Protease In Complex Wit1.1e-4292.999 *D%G
3oudBMdr769 Hiv-1 Protease Complexed With CaP2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.3e-4284.899 *N%G
2rkfA, 2rkfBHiv-1 Pr Resistant Mutant + Lpv1.9e-4284.899 *D%G
2fddA, 2fddBHiv Protease D545701 Bound With Gw03852.3e-4283.899 *D%G
4ep2A, 4ep3A, 4epjAInactive Single Chain Wild-Type Hiv-1 Pr3.6e-4290.999 *N%G
2p3cA, 2p3cBThe Subtype F Wild Type Hiv Protease Com6.9e-4285.999 *D%G
4eq0A, 4eqjAInactive Single Chain Variant Of Hiv-1 P7.6e-4289.999 *N%G
2j9jA, 2j9kA, 2j9kB, 3dcrA, 3dcrB, 3hauA, 3hauBAtomic-Resolution Chemically-Synthesized2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-4190.999 *D%G
2rkgA, 2rkgBHiv-1 Pr Resistant Mutant + Lpv1.8e-4184.0100 *D%G
2o40AA Chemically Synthesized 203 Amino Acid 2.8e-4190.999 *D%G
3ka2AChemically Synthesized 203 Amino Acid 'c2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4190.999 *D%G
3nxeA, 3nxnAEster Chemical Analogue 'covalent Dimer'2.8e-4190.999 *D%G
3hzcA, 3iawA, 3hloAA Chemically Synthesized 203 Amino Acid 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.8e-4190.999 *D%G
3i2lA, 3i2lB, 3nwqA, 3nwqB, 3nwxA, 3nwxBA Chemically Synthesized [allo-Ile5050']2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.163.7e-4189.999 *D%G
3dckA, 3dckB, 3ia9A, 3ia9BD25n Chemical Analogue Of Hiv-1 Protease3.7e-4189.999 *N%G
2j9jBAtomic-Resolution Chemically-Synthesized2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.164.4e-4189.999 *D%G
3hawA, 3hawB[l-Ala5151']HIV-1 Protease With Reduced 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.165.3e-4189.999 *D%G
3u7sA, 3u7sBHiv Pr Drug Resistant Patient's Variant 7.7e-4178.899 *D%G
3hdkA, 3hdkB, 3hboA, 3hboB, 3nygA, 3nygBChemically Synthesized [aib5151']HIV-1 P7.7e-4189.999 *D%G
3fsmA, 3gi0A, 3gi0BA Chemically Synthesized 203 Amino Acid 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-4089.999 *D%G
3gguA, 3gguBHiv Pr Drug Resistant Patient's Variant 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.166e-4078.899 *D%G
3ucbA, 3ucbB, 3uf3A, 3uf3B, 3ufnA, 3ufnB, 3uhlA, 3uhlB, 3uhlC, 3uhlD, 4j54A, 4j54B, 4j55A, 4j55B, 4j5jA, 4j5jBMultidrug Resistant Hiv-1 Protease Clini1.5e-3978.899 *D%G
2p3dA, 2p3dBThe Multi-Drug Resistant Mutant Subtype 4.6e-3977.899 *D%G
3t3cA, 3t3cBHiv Pr Resistant Patient Derived Mutant 4.6e-3976.899 *D%G
3mwsA, 3mwsBGroup N Hiv-1 Protease1.3e-3778.899 *D%G
2samAThe Protease From Simian Immunodeficienc1e-2352.599 *D%G
1sipAAlternative Native Flap Conformation Rev1e-2351.599 *D%G
1ytiA, 1ytjA, 1az5ASiv Protease Crystallized With Peptide P2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.161.2e-2351.599 *D%G
1sivA, 1sivB, 1tcwA, 1tcwBThree-Dimensional A Siv Protease(Slash)i2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.162.6e-2350.599 *D%G
2mipA, 2mipB, 2mipC, 2mipD, 1idaA, 1idaB, 1idbA, 1idbB, 1hiiA, 1hiiB, 1hshA, 1hshB, 1hshC, 1hshD, 1hsiA, 1hsiB, 1jldA, 1jldB, 3ebzA, 3ebzB, 3ec0A, 3ec0B, 3ecgA, 3ecgB, 3s45A, 3s45BHuman Immunodeficiency Virus (Hiv) Type 2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.473.5e-2249.599 *D%G
1ivpA, 1ivpB, 1ivqA, 1ivqB, 2hpeA, 2hpeB, 2hpfA, 2hpfB, 4upjA, 4upjB, 3upjA, 3upjB, 6upjA, 6upjB, 5upjA, 5upjBThe Crystallographic The Protease From H2.7.7.49, 2.7.7.7, 3.1.13.2, 3.1.26.13, 3.4.23.471.1e-2149.599 *D%G
2hahAThe Fiv 12s Protease In Complex With Tl-2.7.7.49, 3.1.13.2, 3.1.26.13, 3.6.1.239.4e-0738.5109 *D%G
1baiA, 1baiBRous Sarcoma Virus Protease In Complex W3.1e-0644.490 *D%G
1fmbA, 2fmbAEiav Protease Complexed With The Inhibit2.7.7.49, 3.1.13.2, 3.1.26.131.6e-0532.399 *D%G
3nr6A, 3nr6B, 3slzA, 3slzB, 3sm1A, 3sm1B, 3sm2A, 3sm2B, 4exhA, 4exhBXenotropic Murine Leukemia Virus-Related2.7.7.49, 2.7.7.7, 3.1.26.40.000229.392 *D%G

Proteins identified as mutant are highlighted in maroon. Conservative changes in active site residues, e.g. &K, are marked in green. Non-conservative changes to active site residues (&A) are highlighted in red. Library sequence residues identical to MACie active site residues are shown in grey.

Likewise, E.C. numbers identical to the MACiE protein are shown in grey; differences in black.


Homologs in PDB for MACiE ID:


Contact Us Glossary of Terms Useful Links Statistics Documentation More about MACiE
spacer
spacer